{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:50:35Z","timestamp":1774363835090,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd004246.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T00:00:00Z","timestamp":1481328000000}}],"reference-count":73,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004246.pub4","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T12:55:40Z","timestamp":1481374540000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-na\u00efve individuals"],"prefix":"10.1002","volume":"2016","author":[{"given":"Lawrence","family":"Mbuagbaw","sequence":"first","affiliation":[{"name":"Yaound\u00e9 Central Hospital; Centre for the Development of Best Practices in Health (CDBPH); Henri Dunant Avenue PO Box 87 Yaound\u00e9 Cameroon"},{"name":"McMaster University; Department of Clinical Epidemiology and Biostatistics; Hamilton ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Mursleen","sequence":"additional","affiliation":[{"name":"McMaster University; Department of Clinical Epidemiology and Biostatistics; Hamilton ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H","family":"Irlam","sequence":"additional","affiliation":[{"name":"University of Cape Town; Primary Health Care Directorate; E47 OMB Groote Schuur Hospital Cape Town Western Cape South Africa 7925"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicen B","family":"Spaulding","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases; Laboratory of Clinical Infectious Diseases; 2953 TERRACE DR Bethesda MD USA 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George W","family":"Rutherford","sequence":"additional","affiliation":[{"name":"University of California, San Francisco; Global Health Sciences; 50 Beale Street Suite 1200 San Francisco California USA 94105"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandi","family":"Siegfried","sequence":"additional","affiliation":[{"name":"Cape Town South Africa"},{"name":"Medical Research Council; Alcohol, Tobacco and Other Drug Research Unit; Francie van Zijl Drive Tygerberg South Africa 7505"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,12,10]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD004246.pub4-BIB0001|cit1","first-page":"24","article-title":"[Nevirapine or efavirenz in combination with two nucleoside analogues in HIV-infected antiretroviral-na\u00efve patients]","volume":"20","author":"Ayala Gayt\u00e1n","year":"2004","journal-title":"Medicina Interna de M\u00e9xico"},{"issue":"4","key":"10.1002\/14651858.CD004246.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1473-3099(13)70007-0","article-title":"Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial","volume":"13","author":"Bonnet","year":"2013","journal-title":"Lancet Infectious diseases"},{"issue":"1","key":"10.1002\/14651858.CD004246.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3851\/IMP2675","article-title":"Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial","volume":"19","author":"Landman","year":"2014","journal-title":"Antiviral Therapy"},{"issue":"12","key":"10.1002\/14651858.CD004246.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1086\/599114","article-title":"A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study","volume":"48","author":"Manosuthi","year":"2009","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0005|cit5","unstructured":"Mateelli A Kouanda S Saleri N Ouedraogo G Efficacy and safety of nevirapine- vs efavirenz based ART in TB\/HIV patients in Burkina Faso: a clinical and pharmacokinetic study 20th Conference on Retroviruses and Opportunistic Infections. 3-16 March, 2013 Atlanta, USA 2013 Abstract 47462"},{"issue":"3","key":"10.1002\/14651858.CD004246.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1310\/0CJ5-2ABQ-CB00-6MR6","article-title":"SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected na\u00efve individuals","volume":"3","author":"N\u00fa\u00f1ez","year":"2002","journal-title":"HIV Clinical Trials"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/1471-2334-13-482","article-title":"Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-na\u00efve patients with HIV and tuberculosis infections in India: a pilot study","volume":"13","author":"Sinha","year":"2013","journal-title":"BMC Infectious Diseases"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0008|cit8","unstructured":"Sow PG Badiane M Diallo PD Lo I Ndiaye B Gaye AM Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584] XVI International AIDS Conference; 13-18 August, 2006 Toronto, Canada 2006"},{"issue":"7","key":"10.1002\/14651858.CD004246.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/cid\/cir447","article-title":"Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial","volume":"53","author":"Swaminathan","year":"2011","journal-title":"Clinical infectious disease"},{"issue":"5","key":"10.1002\/14651858.CD004246.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1310\/hct0905-324","article-title":"Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons","volume":"9","author":"Berg-Wolf","year":"2008","journal-title":"HIV Clinical Trials"},{"issue":"9417","key":"10.1002\/14651858.CD004246.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"Leth","year":"2004","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/01.aids.0000366080.91192.55","article-title":"Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana","volume":"24 Suppl 1","author":"Wester","year":"2010","journal-title":"AIDS (London, England)"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0013|cit13","unstructured":"Antela A Iribarren JA Mahillo B Santos I Ribera E Gutierrez C Final analysis of a prospective, randomized, open-label, multicentre trial in na\u00efve, HIV-1-infected patients, comparing ZDV\/3TC vs d4T\/ddI, plus efavirenz, nevirapine or indinavir\/ritonavir (AMADEUS 01 study) International Conference on AIDS; 11-16 July, 2004; Bangkok, Thailand 2004 Abstract no. B11920"},{"issue":"3","key":"10.1002\/14651858.CD004246.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAD.0b013e3282f3cc35","article-title":"Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA","volume":"22","author":"Bannister","year":"2008","journal-title":"AIDS (London, England)"},{"issue":"12","key":"10.1002\/14651858.CD004246.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"e84585","DOI":"10.1371\/journal.pone.0084585","article-title":"Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcome","volume":"8","author":"Bonnet","year":"2013","journal-title":"PLOS ONE"},{"issue":"7","key":"10.1002\/14651858.CD004246.pub4-BIB0016|cit16","first-page":"343","article-title":"Hepatotoxicity in patients prescribed efavirenz or nevirapine","volume":"13","author":"Br\u00fcck","year":"2008","journal-title":"European Journal of Medical Research"},{"issue":"6","key":"10.1002\/14651858.CD004246.pub4-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1089\/aid.2007.0295","article-title":"Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients","volume":"24","author":"Beaudrap","year":"2008","journal-title":"AIDS Research and Human Retroviruses"},{"issue":"11","key":"10.1002\/14651858.CD004246.pub4-BIB0018|cit18","first-page":"760","article-title":"Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China","volume":"85","author":"Han","year":"2005","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"6","key":"10.1002\/14651858.CD004246.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1258\/0956462054094060","article-title":"Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort)","volume":"16","author":"Hartmann","year":"2005","journal-title":"International Journal of STD & AIDS"},{"issue":"9","key":"10.1002\/14651858.CD004246.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00105-005-0911-z","article-title":"Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz","volume":"56","author":"Hartmann","year":"2005","journal-title":"Der Hautarzt"},{"issue":"10","key":"10.1002\/14651858.CD004246.pub4-BIB0021|cit21","first-page":"912","article-title":"[Effect of highly active anti-retroviral therapy on prevention of mother to child transmission of HIV and on infant growth and development]","volume":"45","author":"He","year":"2011","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]"},{"issue":"6","key":"10.1002\/14651858.CD004246.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ijid.2007.10.008","article-title":"Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children","volume":"12","author":"Lapphra","year":"2008","journal-title":"International Journal of Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD004246.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00126334-200404150-00007","article-title":"Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study","volume":"35","author":"Manfredi","year":"2004","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"6","key":"10.1002\/14651858.CD004246.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1310\/EWWC-YLJ6-8LHE-054A","article-title":"Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine","volume":"6","author":"Manfredi","year":"2005","journal-title":"HIV Clinical Trials"},{"issue":"17","key":"10.1002\/14651858.CD004246.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1097\/QAD.0b013e3280110cae","article-title":"Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells\/microl","volume":"20","author":"Manfredi","year":"2006","journal-title":"AIDS"},{"issue":"3","key":"10.1002\/14651858.CD004246.pub4-BIB0026|cit26","first-page":"651","article-title":"Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen","volume":"42","author":"Mankhatitham","year":"2011","journal-title":"Southeast Asian Journal of Tropical Medicine and Public Health"},{"issue":"2","key":"10.1002\/14651858.CD004246.pub4-BIB0027|cit27","first-page":"163","article-title":"Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy","volume":"95","author":"Mankhatitham","year":"2012","journal-title":"Chotmaihet thangphaet [Journal of the Medical Association of Thailand]"},{"issue":"2","key":"10.1002\/14651858.CD004246.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1468-1293.2004.00195.x","article-title":"Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-na\u00efve patients with advanced HIV infection","volume":"5","author":"Manosuthi","year":"2004","journal-title":"HIV Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004246.pub4-BIB0029|cit29","first-page":"45","article-title":"Serial monitoring of drug concentrations while on and off rifampicin between standard doses of nevirapine based and efavirenz-based antiretroviral regimens","volume":"10","author":"Manosuthi","year":"2009","journal-title":"HIV Medicine"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004246.pub4-BIB0030|cit30","first-page":"18290","article-title":"Differences in body circumferences, skin-fold thicknesses and lipid profiles among HIV-infected African children on and not on stavudine","volume":"15","author":"Musiime","year":"2012","journal-title":"Journal of the International AIDS Society"},{"issue":"16","key":"10.1002\/14651858.CD004246.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1097\/QAD.0b013e328310407e","article-title":"Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults","volume":"22","author":"Nachega","year":"2008","journal-title":"AIDS"},{"issue":"6","key":"10.1002\/14651858.CD004246.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/135965350400900602","article-title":"Alteration of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study","volume":"9","author":"Negredo","year":"2004","journal-title":"Antiviral Therapy"},{"issue":"12","key":"10.1002\/14651858.CD004246.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"e1154","DOI":"10.1016\/j.ijid.2013.08.006","article-title":"Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy","volume":"17","author":"Padmapriyadarsini","year":"2013","journal-title":"International Journal of Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD004246.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1473-3099(10)70313-3","article-title":"First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2\/3trial","volume":"11","author":"Babiker","year":"2011","journal-title":"Lancet Infect Diseases"},{"issue":"7","key":"10.1002\/14651858.CD004246.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/QAD.0b013e328345e56b","article-title":"Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy","volume":"25","author":"Prendergast","year":"2011","journal-title":"AIDS"},{"issue":"3","key":"10.1002\/14651858.CD004246.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/INF.0b013e31818dd72b","article-title":"Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less","volume":"28","author":"Puthanakit","year":"2009","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"6","key":"10.1002\/14651858.CD004246.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/INF.0b013e318194eea6","article-title":"Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy","volume":"28","author":"Puthanakit","year":"2009","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0038|cit38","unstructured":"Swaminathan S Padmapriyadarsini C Venkatesan P Narendran G Ramesh Kumar S Iliayas S Once-daily nevirapine vs efavirenz in the treatment of HIV-infected patients with TB: a randomized clinical trial 16th conference on retroviruses and opportunistic infections. Montreal, Canada, February 8-11, 2009. 2009"},{"issue":"5","key":"10.1002\/14651858.CD004246.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1258\/ijsa.2007.007236","article-title":"Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002)","volume":"19","author":"Beck","year":"2008","journal-title":"International Journal of STD & AIDS"},{"issue":"4","key":"10.1002\/14651858.CD004246.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1046\/j.1464-2662.2001.00083.x","article-title":"Guidelines for the treatment of HIV-infected adults with antiretroviral therapy","volume":"2","author":"BHIVA Writing Committee","year":"2001","journal-title":"HIV Medicine"},{"issue":"9546","key":"10.1002\/14651858.CD004246.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(06)69638-4","article-title":"Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses","volume":"368","author":"Chou\u00a0R","year":"2006","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004246.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2007.00426.x","article-title":"Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review","volume":"8","author":"Cooper","year":"2007","journal-title":"HIV Medicine"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/00042560-200103011-00004","article-title":"International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance","volume":"26 Suppl 1","author":"Deeks","year":"2001","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0044|cit44","unstructured":"Department of Health and Human Sciences AIDSinfo Drug Database https:\/\/aidsinfo.nih.gov\/drugs\/116\/nevirapine\/0\/professional"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0045|cit45","unstructured":"Department of Health and Human Sciences AIDSinfo Drug Database https:\/\/aidsinfo.nih.gov\/drugs\/269\/efavirenz\/0\/professional"},{"issue":"RR-7","key":"10.1002\/14651858.CD004246.pub4-BIB0046|cit46","first-page":"1","article-title":"Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV","volume":"51","author":"Dybul","year":"2002","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"7109","key":"10.1002\/14651858.CD004246.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical research ed.)"},{"issue":"9534","key":"10.1002\/14651858.CD004246.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(06)69158-7","article-title":"The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings","volume":"368","author":"Gilks","year":"2006","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0049|cit49","unstructured":"GRADE Working Group, McMaster University GRADEpro GDT 2014"},{"issue":"7650","key":"10.1002\/14651858.CD004246.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0051|cit51","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"issue":"9061","key":"10.1002\/14651858.CD004246.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0140-6736(05)62505-6","article-title":"Decline in deaths from AIDS due to new antiretrovirals","volume":"349","author":"Hogg","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijid.2014.04.020","article-title":"Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis","volume":"25","author":"Jiang","year":"2014","journal-title":"International Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0054|cit54","unstructured":"Lau B Gange S Kirk G Mehta S Merriman B Moore R Predictive value of plasma HIV RNA levels for rate of CD4 decline and clinical disease progression 14th Conference on Retroviruses and Opportunistic Infections (CROI); 25-28 February, 2007; Los Angeles, California 2007"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0055|cit55","unstructured":"Mellors J Margolick J Phair J Rinaldo C Detels R Jaconson L Comparison of plasma HIV-1 RNA, CD4 cell count, and CD38 expression on CD8 T cells as predictors of progression to AIDS and CD4 cell decline among untreated participants in the multicenter AIDS cohort study 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February, 2007; Los Angeles, California 2007"},{"issue":"9142","key":"10.1002\/14651858.CD004246.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(98)03201-2","article-title":"Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group","volume":"352","author":"Mocroft","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004246.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00001432-200002000-00004","article-title":"Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection","volume":"13","author":"Moyle","year":"2000","journal-title":"Current Opinion in Infectious Diseases"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0058|cit58","volume-title":"Table for Grading the Severity of Adult and Pediatric Adverse Events","author":"Division of","year":"2004"},{"issue":"7","key":"10.1002\/14651858.CD004246.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"e68995","DOI":"10.1371\/journal.pone.0068995","article-title":"Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis","volume":"8","author":"Pillay","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0060|cit60","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"9","key":"10.1002\/14651858.CD004246.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/QAD.0b013e32835f1db0","article-title":"Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis","volume":"27","author":"Shubber","year":"2013","journal-title":"AIDS (London, England)"},{"issue":"2","key":"10.1002\/14651858.CD004246.pub4-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004535.pub2","article-title":"Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults","author":"Siegfried","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0063|cit63","unstructured":"UNAIDS AIDS by the numbers 2015 http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/AIDS-by-the-numbers-2016_en.pdf"},{"issue":"9","key":"10.1002\/14651858.CD004246.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/00002030-200106150-00003","article-title":"High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals","volume":"15","author":"Veldkamp","year":"2001","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0065|cit65","unstructured":"World Health Organization Scaling up antiretroviral therapy in low in resource-limited settings. Guidelines for a public health approach. June 2002 http:\/\/www.who.int\/hiv\/pub\/prev_care\/en\/ScalingUp_E.pdf"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0066|cit66","unstructured":"World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision http:\/\/whqlibdoc.who.int\/publications\/2006\/9789241594677_eng.pdf"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0067|cit67","unstructured":"World Health Organization Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. November 2009 http:\/\/www.who.int\/hiv\/pub\/arv\/rapid_advice_art.pdf"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0068|cit68","unstructured":"World Health Organization Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. July 2014 http:\/\/www.who.int\/hiv\/pub\/guidelines\/keypopulations\/en\/"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0069|cit69","unstructured":"World Health Organization WHO Model List of Essential Medicines. 19th List http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/EML_2015_FINAL_amended_NOV2015.pdf?ua=1"},{"key":"10.1002\/14651858.CD004246.pub4-BIB0070|cit70","unstructured":"World Health Organization Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Second edition http:\/\/www.who.int\/hiv\/pub\/arv\/arv-2016\/en\/"},{"issue":"2","key":"10.1002\/14651858.CD004246.pub4-BIB0071|cit71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004246.pub2","article-title":"Efavirenz versus nevirapine as a non-nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection","author":"Mbuagbaw","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD004246.pub4-BIB0072|cit72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004246.pub3","article-title":"Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-na\u00efve individuals","author":"Mbuagbaw","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD004246.pub4-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004246","article-title":"Efavirenz versus nevirapine as a non-nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection","author":"Neuwelt","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD004246.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T21:09:55Z","timestamp":1658005795000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004246.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Infectious Diseases Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,12,10]]},"references-count":73,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004246.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,10]]}}}